Related references
Note: Only part of the references are listed.Serious Infectious Events and Immunoglobulin Replacement Therapy in Patients With Autoimmune Disease Receiving Rituximab: A Retrospective Cohort Study
Sarah Stabler et al.
CLINICAL INFECTIOUS DISEASES (2021)
Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia
Giorgio Ottaviano et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome
Cyrielle Parmentier et al.
PEDIATRIC NEPHROLOGY (2020)
Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
Khalaf Kridin et al.
AUTOIMMUNITY REVIEWS (2020)
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases
Md Yuzaiful Md Yusof et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values
Pierluigi Marzuillo et al.
WORLD JOURNAL OF CLINICAL CASES (2019)
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
Amer M. Khojah et al.
PEDIATRIC RHEUMATOLOGY (2019)
Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux
Samuel Deshayes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Primary immunodeficiency disease: a retrospective study of 112 Chinese children in a single tertiary care center
Jinhong Wu et al.
BMC PEDIATRICS (2019)
Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab
Kleber Jordao de Souza et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2018)
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
E. C. Tallantyre et al.
JOURNAL OF NEUROLOGY (2018)
Prevalence and Outcomes of Primary Immunodeficiency in Hospitalized Children in the United States
Zachary Rubin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2018)
Marginal-Zone B-Cells Are Main Producers of IgM in Humans, and Are Reduced in Patients With Autoimmune Vasculitis
Daniel Appelgren et al.
FRONTIERS IN IMMUNOLOGY (2018)
Outcomes of rituximab therapy in refractory lupus: A meta-analysis
Fatma Alshaiki et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2018)
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
Sara Barmettler et al.
JAMA NETWORK OPEN (2018)
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies
Alain Fischer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy et al.
ARTHRITIS CARE & RESEARCH (2017)
Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis
Jens Thiel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
Shivani Shah et al.
CLINICAL KIDNEY JOURNAL (2017)
Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome
Shuichiro Fujinaga et al.
CLINICAL NEPHROLOGY (2016)
Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles
Emilie Reboursiere et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies
Jolan E. Walter et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2016)
Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura
E. Becerra et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab-for how long?
Sara Barmettler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Practice parameter for the diagnosis and management of primary immunodeficiency
Francisco A. Bonilla et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
Darren M. Roberts et al.
JOURNAL OF AUTOIMMUNITY (2015)
Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series
Darren M. Roberts et al.
JOURNAL OF AUTOIMMUNITY (2015)
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study
Federico De Angelis et al.
LEUKEMIA RESEARCH (2015)
Hypogammaglobulinemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: A Cytokine Mediated Immunoglobulin Isotype Class Switch Arrest?
Mikael Sundin et al.
PEDIATRIC BLOOD & CANCER (2015)
Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?
Jennifer Worch et al.
CANCERS (2015)
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
Helena Marco et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement
Sai S. Duraisingham et al.
PLOS ONE (2014)
Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes
M. Makatsori et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2014)
Immunoglobulin replacement therapy in secondary hypogammaglobulinemia
Nicolo Compagno et al.
FRONTIERS IN IMMUNOLOGY (2014)
Incidence and risk factors for hypogammaglobulinemia in pediatric patients following allo-SCT
H. Frangoul et al.
BONE MARROW TRANSPLANTATION (2013)
Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
Carla Casulo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Maria J. Leandro
ARTHRITIS RESEARCH & THERAPY (2013)
Carbamazepine-induced hypogammaglobulinemia
Nihal Ozaras et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2012)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab
Henrik E. Mei et al.
BLOOD (2010)
B-cell targeted therapies in human autoimmune diseases: an updated perspective
Michael J. Townsend et al.
IMMUNOLOGICAL REVIEWS (2010)
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2010)
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
C. Salliot et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Rituximab in the treatment of autoimmune haematological disorders
Bernadette Garvey
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias
Aarati Rao et al.
PEDIATRIC BLOOD & CANCER (2008)
B cell depletion therapy in systemic lupus erythematosus - Effect on autoantibody and antimicrobial antibody profiles
G. Cambridge et al.
ARTHRITIS AND RHEUMATISM (2006)
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
F. Cabanillas et al.
ANNALS OF ONCOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia
SH Lim et al.
BONE MARROW TRANSPLANTATION (2005)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
